Evidence map›Paper›PMID 40696364›Full record

ArticleBMC public health2025

Stakeholder perspectives on scaling up potassium-enriched salt to reduce cardiovascular disease in Australia: a qualitative study.

Juliette Crowther, Annet C Hoek, Kathy Trieu, Inez Denham, Irene Deltetto, Alain Balaguer-Mercado, James D Bullen, Katrina Kissock, Dori Patay, Emalie Rosewarne and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Juliette CrowtherThe George Institute for Global Health, University of New South Wales, Sydney, Australia. jcrowther@georgeinstitute.org.au.
Annet C HoekThe George Institute for Global Health, University of New South Wales, Sydney, Australia.
Kathy TrieuThe George Institute for Global Health, University of New South Wales, Sydney, Australia.
Inez DenhamHealth Technology Analysts Pty Ltd, Surry Hills, Australia.
Irene DeltettoHealth Technology Analysts Pty Ltd, Surry Hills, Australia.
Alain Balaguer-MercadoBusiness School, University of New South Wales, Sydney, Australia.
James D BullenThe George Institute for Global Health, University of New South Wales, Sydney, Australia.
Katrina KissockThe George Institute for Global Health, University of New South Wales, Sydney, Australia.
Dori PatayThe George Institute for Global Health, University of New South Wales, Sydney, Australia.
Emalie RosewarneThe George Institute for Global Health, University of New South Wales, Sydney, Australia.
Simone PettigrewThe George Institute for Global Health, University of New South Wales, Sydney, Australia.
Bruce NealThe George Institute for Global Health, University of New South Wales, Sydney, Australia.
Jacqui WebsterThe George Institute for Global Health, University of New South Wales, Sydney, Australia.

Funding

Ian Potter Foundation 21689National Health and Medical Research Council,Australia 2018015
6 · The paper itself

Abstract

backgroundCardiovascular disease, the world's leading cause of death, could be significantly reduced through sodium reduction strategies; however, the implementation of such strategies has had limited impact in Australia and globally. Switching to potassium-enriched salt is a highly promising intervention, but uptake by the food industry and consumers remains limited. This study investigated the barriers and enablers for scaling up potassium-enriched salt use in Australia.

methodsA qualitative, theory-informed study design was used to conduct 24 semi-structured interviews with representatives from civil society, government, and industry. Interviewees discussed scaling up potassium-enriched salt in relation to their interests, ideas, existing policies and guidelines, and perceived challenges and opportunities within the Australian context. Data were analysed using thematic analysis.

resultsMinimal knowledge and awareness of potassium-enriched salt among all stakeholder groups was the most prominent finding. The key perceived barriers were low consumer demand for potassium-enriched salt products and little incentive for industry to invest in supply. Further, government stakeholders expressed hesitancy to implement policies due to perceived health risks such as hyperkalaemia. Interviewees identified increased awareness, support for industry research and development, and leveraging current policies and initiatives (such as the Australian Health Star Rating system) as potential enablers.

conclusionImproving stakeholder understanding of the benefit of switching to potassium-enriched salt in Australia may require a coordinated advocacy strategy that disseminates the evidence and addresses misconceptions. Efforts to drive increased supply and demand could be advanced using a multi-sectoral approach that focuses on supporting industry uptake, encouraging consumer demand, and informing policy implementation.

Indexed as

Cardiovascular DiseasesPotassium, DietarySodium Chloride, DietaryStakeholder ParticipationAustraliaHealth Knowledge, Attitudes, PracticeHumansInterviews as TopicQualitative ResearchPotassium, DietarySodium Chloride, DietaryCardiovascular diseaseCivil society perspectiveFood policyGovernment perspectiveHypertensionIndustry perspectivePotassium-enriched saltPublic health interventionSalt replacementSodium reduction

Identifiers

PMID40696364
PMCPMC12281820

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.